Biogen (BIIB)

• Market cap: $17.7B
• 1 day: 0.76%
• 5 days: 1.36%
• 1 month: -11.52%
• 3 months: -17.20%
• 6 months: -33.17%
• Year to date: -19.28%
• 1 year: -43.64%
• 5 years: -59.21%
• 10 years: -67.62%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,605

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

3.13% more ownership

Funds ownership: 86.97% [Q3] → 90.1% (+3.13%) [Q4]

7% less repeat investments, than reductions

Existing positions increased: 291 | Existing positions reduced: 313

5% less funds holding

Funds holding: 897 [Q3] → 851 (-46) [Q4]

13% less call options, than puts

Call options by funds: $308M | Put options by funds: $356M

18% less capital invested

Capital invested by funds: $24.5B [Q3] → $20.1B (-$4.4B) [Q4]

19% less first-time investments, than exits

New positions opened: 128 | Existing positions closed: 158

50% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 4 (-4) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $115 5% downside
• Avg. target: $186 53% upside
• High target: $265 119% upside

11 analyst ratings

• positive: 6 55%
• neutral: 5 45%
• negative: 0 0%

Truist Securities Srikripa Devarakonda 32% 1-year accuracy 11 / 34 met price target	64% upside $199	Buy Maintained	29 Apr 2025
Piper Sandler Christopher Raymond 26% 1-year accuracy 7 / 27 met price target	5% downside $115	Neutral Maintained	29 Apr 2025
Goldman Sachs Salveen Richter 20% 1-year accuracy 4 / 20 met price target	63% upside $197	Buy Maintained	23 Apr 2025
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target	86% upside $225	Outperform Maintained	22 Apr 2025
Morgan Stanley Matthew Harrison 43% 1-year accuracy 10 / 23 met price target	26% upside $152	Equal-Weight Maintained	9 Apr 2025